This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2003 Jan;17(1):5-6.

doi: 10.1023/a:1024295422944.

Drugs to promote sinus rhythm reversion and maintenance in atrial fibrillation--why amiodarone is better

PMID: 12916518
DOI: 10.1023/a:1024295422944

Comparative Study

Drugs to promote sinus rhythm reversion and maintenance in atrial fibrillation--why amiodarone is better

Stanley Nattel. Cardiovasc Drugs Ther. 2003 Jan.

. 2003 Jan;17(1):5-6.

doi: 10.1023/a:1024295422944.

Author

PMID: 12916518
DOI: 10.1023/a:1024295422944

No abstract available

PubMed Disclaimer

Comment on

Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study.
Manios EG, Mavrakis HE, Kanoupakis EM, Kallergis EM, Dermitzaki DN, Kambouraki DC, Vardas PE. Manios EG, et al. Cardiovasc Drugs Ther. 2003 Jan;17(1):31-9. doi: 10.1023/a:1024203824761. Cardiovasc Drugs Ther. 2003. PMID: 12843685 Clinical Trial.

Similar articles

Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study.
Villani GQ, Piepoli MF, Terracciano C, Capucci A. Villani GQ, et al. Am Heart J. 2000 Sep;140(3):e12. doi: 10.1067/mhj.2000.107179. Am Heart J. 2000. PMID: 10966543 Clinical Trial.
Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study.
Manios EG, Mavrakis HE, Kanoupakis EM, Kallergis EM, Dermitzaki DN, Kambouraki DC, Vardas PE. Manios EG, et al. Cardiovasc Drugs Ther. 2003 Jan;17(1):31-9. doi: 10.1023/a:1024203824761. Cardiovasc Drugs Ther. 2003. PMID: 12843685 Clinical Trial.
Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance.
Galperín J, Elizari MV, Chiale PA, Molina RT, Ledesma R, Scapín AO, Blanco MV, Bonato R, Lago M; Grupo de Estudio de Fibrilación Auricular Con Amiodarona (GEFACA) Investigators. Galperín J, et al. J Cardiovasc Pharmacol Ther. 2003 Sep;8(3):179-86. doi: 10.1177/107424840300800302. J Cardiovasc Pharmacol Ther. 2003. PMID: 14506542
Etiology, pathophysiology, and treatment of atrial fibrillation: part 1.
Aronow WS. Aronow WS. Cardiol Rev. 2008 Jul-Aug;16(4):181-8. doi: 10.1097/CRD.0b013e31816de1e3. Cardiol Rev. 2008. PMID: 18562808 Review.
[Drug therapy of atrial fibrillation: control of heart rate versus establishing sinus rhythm].
Steinbeck G. Steinbeck G. Z Kardiol. 1996;85 Suppl 6:69-74. Z Kardiol. 1996. PMID: 9064985 Review. German.

See all similar articles

Cited by

Vanoxerine: cellular mechanism of a new antiarrhythmic.
Lacerda AE, Kuryshev YA, Yan GX, Waldo AL, Brown AM. Lacerda AE, et al. J Cardiovasc Electrophysiol. 2010 Mar;21(3):301-10. doi: 10.1111/j.1540-8167.2009.01623.x. Epub 2009 Oct 8. J Cardiovasc Electrophysiol. 2010. PMID: 19817928 Free PMC article.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information